EICHORCondition: Advanced Cancer · Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers
This description comes directly from the study's public registry record.
Li Zhang, Doctor · 020-87343458 · zhangli@sysucc.org.cn
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Subjects voluntarily join this study, sign the informed consent form, and have good compliance； * Age: 18-75 years; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expected survival of more than 3 months； * Histologically or cytologically diagnosed with advanced cancers; * Subjects with advanced malignancies who have failed standard therapy or lack effective treatment; * Major organs are functioning well; * Female and male subjects of childbearing potential should agree to practice contraception during the study and until 6 months after the completion of the study. Exclusion Criteria: * Current concomitant or ever presented with other malignancies within 2 years prior to the first dose; * Unresolved toxicity of Grade 1 or above according to CTCAE due to any prior anti-tumor therapy; * Significant surgical treatment, biopsy, or significant traumatic injury within 28 days prior to the first dose; * Long-term unhealed wounds or fractures * Cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose; * A history of psychotropic drug abuse and cannot be abstained, or have a mental disorder; * Subjects with any severe and/or uncontrolled disease; * History of live attenuated vaccination within 2 weeks prior to the first dose or planned live attenuated vaccination during the study; * Previous history of unexplained severe allergies, hypersensitivity to monoclonal antibodies or exogenous human immunoglobulins, or hypersensitivity to TQB2922 for injection or its excipients; * According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the patients or affect the completion of the study, or subjects who are considered to be unsuitable for enrollment for other reasons.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| The first affiliated hospital of Guangzhou medical university | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Henan Provincine People's Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Not Yet Recruiting |
| The Second Xiangya Hospital of Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
| Affiliated Zhongshan Hospital of Dalian University | Dalian, Liaoming, China | Not Yet Recruiting |
| Department of Medical Oncology, The First Hospital of China Medical University | Shenyang, Liaoning, China | Not Yet Recruiting |
+ 5 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06188624